Navigation Links
AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
Date:7/2/2008

Biotech innovator develops new therapies based on cells manufactured from

bone marrow; SV Life Sciences and Novo A/S provide funding round

SALT LAKE CITY and HAMBURG, Germany, July 2 /PRNewswire/ -- AlloCure Inc., a biotechnology company at the forefront of innovative cell therapies for the treatment of acute kidney injury, today announced the closing of a $14.5MM Series A financing. The round was led by SV Life Sciences with Novo A/S joining the syndicate.

"This financing represents a significant step forward in developing the first cell therapy to effectively treat patients who are suffering from acute kidney injury," said John Wirthlin President and CEO. "SV Life Sciences and Novo Ventures bring tremendous depth, experience and clout to our efforts. We look forward to working closely with our investors to successfully commercialize this unique and proprietary technology."

Despite major advances over the past 30 years, acute kidney injury remains treatment resistant and presents a growing critical problem for a significant number of patients around the world.

"AlloCure has not only established itself as a leader in developing cell therapies to treat kidney patients," said Lutz Giebel, Managing Partner of SV Life Sciences. "They have also built an attractive and sound business model addressing this growing and unmet medical need."

The investment is key to furthering the company's promising progress in developing these groundbreaking treatments and entering clinical trials. The company hopes to offer acute kidney injury patients a safe and effective treatment option for this life threatening disease in the not too distant future.

"The AlloCure team has developed an impressive scientific foundation which has enabled it to obtain all the regulatory approvals necessary to begin its Phase I Clinical Trial," said Thomas Dyrberg, Senior Partner at Novo. "We anticipate that substantial clinical progress will be made ove
'/>"/>

SOURCE AlloCure Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
(Date:12/24/2014)... December 23, 2014 On Friday, December ... the Omnibus and Continuing Resolution Appropriations Act of 2015, ... eligible to receive funding through the Congressionally Directed Medical ... (DoD). The Hydrocephalus Association (HA), working in conjunction with ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... such as its definition, classification, application and industry ... process, and product cost structure. Production is separated ... covers upstream raw materials, equipment, downstream client survey, ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report expects ... by 2019. It also provides a carefully analyzed data about ... the market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive CAGR ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... and the University of California at Berkeley may give science ... material expected to play a role in advanced electronic, mechanical ... sheet of carbon rips under stress, it does so ... the phenomenon. Instead of tearing randomly like a piece of ...
... InterMune, Inc. (NASDAQ: ITMN ) today announced that ... will present at the 30th Annual J.P. Morgan Healthcare Conference ... EST / 9:30 a.m. PST.   To access ... interested parties may log on to the investor relations page ...
... Switzerland, Jan. 5, 2012   Selexis SA ... Ph.D., will present at the Biotech Showcase 2012 Conference ... Conference in San Francisco, CA. Dr. Fisch ... Growth Investment" to prospective investors and corporate partners on ...
Cached Biology Technology:Graphene rips follow rules 2Graphene rips follow rules 3Selexis SA to Present at Biotech Showcase 2012 2
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the travel experience ... borders. Over the past decade, ePassports, biometric readers, and ... process through border control via eGates and Automated Passport ... seaports, and land borders across the globe. ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in the APAC ... One major trend emerging in this market is advances ... important to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of cancer cells can be switched on using drugs, ... Center. The finding could lead to a new class ... different cancer types. , Popular new drugs such as ... genetic mutations that express themselves in large amounts, causing ...
... the battle against Alzheimer's disease, physician-scientists at NewYork-Presbyterian ... antibodies in human blood that may help to ... as other neurodegenerative diseases. , The newly ... proteins called "oligomers" that are toxic to brain ...
... the protein complex implicated in autism spectrum disorders, a ... California, San Diego (UCSD) Skaggs School of Pharmacy and ... this complex and contribute to the developmental abnormalities found ... cover article in the June issue of the journal ...
Cached Biology News:U-M researchers discover gene switched off in cancer can be turned on 2U-M researchers discover gene switched off in cancer can be turned on 3Newly discovered antibody may be body's natural defense against Alzheimer's 2Newly discovered antibody may be body's natural defense against Alzheimer's 3Researchers reveal structure of protein altered in autism 2
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
in vitro Translation, Accessory Products...
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Request Info...
Biology Products: